Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer
| Autor: | Mari Iguchi, Tomohiro Ota, Masahiko Shibuya, Akihiko Gemma, Tatsuru Okamura, Kazuhiro Kitamura, Tsuneo Shimokawa, Suguru Hibino, Yukio Hosomi |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Oncology
Male medicine.medical_specialty Lung Neoplasms Time Factors medicine.medical_treatment Antineoplastic Agents Neutropenia Gastroenterology Disease-Free Survival Drug Administration Schedule Refractory Internal medicine Medicine Humans Anthracyclines Lung cancer Infusions Intravenous Survival analysis Aged Retrospective Studies Aged 80 and over Chemotherapy Performance status business.industry Hematology General Medicine Middle Aged medicine.disease Small Cell Lung Carcinoma Survival Analysis Treatment Outcome Drug Resistance Neoplasm Surgery Female Neoplasm Recurrence Local business Amrubicin Febrile neutropenia |
| Zdroj: | International journal of clinical oncology. 14(1) |
| ISSN: | 1341-9625 |
| Popis: | Amrubicin, a totally synthetic 9-aminoanthracycline, was evaluated retrospectively for the treatment of refractory and relapsed small-cell lung cancer (SCLC).Retrospective analysis was performed in 32 patients. Amrubicin was infused over 5 min on days 1-3, with courses repeated at 3- or 4-week intervals. Amrubicin was given at a dose of 45 mg/m(2) per day, 40 mg/m(2) per day, 35 mg/m(2) per day, 30 mg/m(2) per day, or 25 mg/m(2) per day depending on medical conditions (patients' age and performance status [PS]), and the dose was modulated according to myelosuppression.The median number of treatment cycles was 3 (range, 1-6). Seventeen patients (53.1%) had a partial response. Median progression-free survival time for all patients was 96 days, and median survival time was 166 days. Grade 3 or 4 hematologic toxicities comprised neutropenia (78.1%), anemia (65.6%), and thrombocytopenia (50.0%). Febrile neutropenia was observed in 8 patients (25.0%). Nonhematologic toxicities were mild. Treatment-related death was observed in 1 patient.Treatment with amrubicin appeared effective in SCLC patients previously treated with chemotherapy, although it was not necessarily safe, because of myelosuppression. Further research is warranted to investigate amrubicin treatment for patients with SCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink